



Clinical trial results:

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Ranolazine on Major Adverse Cardiovascular Events in Subjects with a History of Chronic Angina Who Undergo Percutaneous Coronary Intervention with Incomplete Revascularization

Summary

EudraCT number	2011-002507-15
Trial protocol	DE SE CZ AT GB BE NL ES IT
Global end of trial date	09 February 2015

Results information

Result version number	v1 (current)
This version publication date	25 February 2016
First version publication date	25 February 2016

Trial information

Trial identification

Sponsor protocol code	GS-US-259-0116
-----------------------	----------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01442038
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Gilead Sciences
Sponsor organisation address	333 Lakeside Drive, Foster City, CA, United States, 94404
Public contact	Clinical Trial Mailbox, Gilead Sciences International Ltd, ClinicalTrialDisclosures@gilead.com
Scientific contact	Clinical Trial Mailbox, Gilead Sciences International Ltd, ClinicalTrialDisclosures@gilead.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	09 February 2015
Is this the analysis of the primary completion data?	Yes
Primary completion date	09 February 2015
Global end of trial reached?	Yes
Global end of trial date	09 February 2015
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of this study is to evaluate the efficacy of ranolazine as compared with placebo when used as part of standard medical therapy in chronic angina subjects with incomplete revascularization post-PCI on the composite of ischemia-driven revascularization or ischemia-driven hospitalization without revascularization.

Protection of trial subjects:

The protocol and consent/assent forms were submitted by each investigator to a duly constituted Independent Ethics Committee (IEC) or Institutional Review Board (IRB) for review and approval before study initiation. All revisions to the consent/assent forms (if applicable) after initial IEC/IRB approval were submitted by the investigator to the IEC/IRB for review and approval before implementation in accordance with regulatory requirements.

This study was conducted in accordance with recognized international scientific and ethical standards, including but not limited to the International Conference on Harmonization guideline for Good Clinical Practice (ICH GCP) and the original principles embodied in the Declaration of Helsinki.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	03 November 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 26
Country: Number of subjects enrolled	Poland: 375
Country: Number of subjects enrolled	Spain: 167
Country: Number of subjects enrolled	Sweden: 44
Country: Number of subjects enrolled	United Kingdom: 33
Country: Number of subjects enrolled	Austria: 27
Country: Number of subjects enrolled	Belgium: 41
Country: Number of subjects enrolled	Czech Republic: 75
Country: Number of subjects enrolled	France: 37
Country: Number of subjects enrolled	Germany: 61
Country: Number of subjects enrolled	Italy: 61
Country: Number of subjects enrolled	United States: 965
Country: Number of subjects enrolled	Russian Federation: 322
Country: Number of subjects enrolled	Israel: 220

Country: Number of subjects enrolled	Canada: 165
Worldwide total number of subjects	2619
EEA total number of subjects	947

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	1433
From 65 to 84 years	1155
85 years and over	31

Subject disposition

Recruitment

Recruitment details:

Participants were enrolled at study sites in the United States, Canada, Europe, Russia, and Israel. The first participant was screened on 03 November 2011. The last study visit occurred on 09 February 2015.

Pre-assignment

Screening details:

2734 participants were screened

Period 1

Period 1 title	Overall study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	Ranolazine
------------------	------------

Arm description:

Ranolazine 500 mg (1 x 500 mg tablet) for 7 days, followed by ranolazine 1000 mg (2 x 500 mg tablet) for the duration of the study (participants receiving a moderate CYP3A4 inhibitor continued to receive ranolazine 500 mg (1 x 500 mg tablet) for the duration of the study)

Arm type	Experimental
Investigational medicinal product name	Ranolazine
Investigational medicinal product code	
Other name	Ranexa®
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Ranolazine 500 mg tablet(s) administered twice daily

Arm title	Placebo
------------------	---------

Arm description:

Ranolazine placebo (1 tablet) for 7 days, followed by ranolazine placebo (2 tablets) for the duration of the study (participants receiving a moderate CYP3A4 inhibitor continued to receive ranolazine placebo (1 tablet) for the duration of the study)

Arm type	Placebo
Investigational medicinal product name	Ranolazine Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Ranolazine placebo tablet(s) administered twice daily

Number of subjects in period 1	Ranolazine	Placebo
Started	1322	1297
Completed	1029	1039
Not completed	293	258
Participant withdrew consent	136	97
Adverse event, non-fatal	26	15
Death	34	29
Investigator-initiated early site closure	44	43
Lost to follow-up	37	51
Investigator's discretion	13	16
Protocol deviation	3	7

Baseline characteristics

Reporting groups

Reporting group title	Ranolazine
-----------------------	------------

Reporting group description:

Ranolazine 500 mg (1 x 500 mg tablet) for 7 days, followed by ranolazine 1000 mg (2 x 500 mg tablet) for the duration of the study (participants receiving a moderate CYP3A4 inhibitor continued to receive ranolazine 500 mg (1 x 500 mg tablet) for the duration of the study)

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Ranolazine placebo (1 tablet) for 7 days, followed by ranolazine placebo (2 tablets) for the duration of the study (participants receiving a moderate CYP3A4 inhibitor continued to receive ranolazine placebo (1 tablet) for the duration of the study)

Reporting group values	Ranolazine	Placebo	Total
Number of subjects	1322	1297	2619
Age categorical			
Units: Subjects			
< 65 Years	714	719	1433
65-74 Years	402	383	785
≥ 75 Years	206	195	401
Age continuous			
Units: years			
arithmetic mean	63.4	63.4	
standard deviation	± 10.51	± 10.06	-
Gender categorical			
Units: Subjects			
Female	276	260	536
Male	1046	1037	2083
Race			
Units: Subjects			
American Indian or Alaska native	0	3	3
Asian	16	10	26
Black or African American	49	43	92
Native Hawaiian or Pacific Islander	2	1	3
White	1203	1196	2399
Other	29	28	57
Not permitted	23	16	39
Ethnicity			
Units: Subjects			
Hispanic or Latino	72	64	136
Not Hispanic or Latino	1219	1208	2427
Not reported	28	24	52
Unknown	3	1	4

End points

End points reporting groups

Reporting group title	Ranolazine
Reporting group description: Ranolazine 500 mg (1 x 500 mg tablet) for 7 days, followed by ranolazine 1000 mg (2 x 500 mg tablet) for the duration of the study (participants receiving a moderate CYP3A4 inhibitor continued to receive ranolazine 500 mg (1 x 500 mg tablet) for the duration of the study)	
Reporting group title	Placebo
Reporting group description: Ranolazine placebo (1 tablet) for 7 days, followed by ranolazine placebo (2 tablets) for the duration of the study (participants receiving a moderate CYP3A4 inhibitor continued to receive ranolazine placebo (1 tablet) for the duration of the study)	

Primary: Time From Randomization to First Occurrence of Ischemia-driven Revascularization or Ischemia-driven Hospitalization Without Revascularization

End point title	Time From Randomization to First Occurrence of Ischemia-driven Revascularization or Ischemia-driven Hospitalization Without Revascularization
End point description: 999 = not calculable. Full Analysis Set: all participants in the Safety Analysis Set (randomized and received at least on dose of study drug), except participants with no qualifying percutaneous coronary intervention (PCI; formerly known as angioplasty with stent)). Time to event distributions were estimated by the Kaplan-Meier (KM) method. 1 month = 28 days; 1 calendar year = 365 days.	
End point type	Primary
End point timeframe: Baseline through end of study (average 90 weeks)	

End point values	Ranolazine	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1317	1287		
Units: percentage of participants				
number (not applicable)				
KM Estimate: 1 Month	3.4	2.3		
KM Estimate: 6 Months	11.3	10		
KM Estimate: 12 Months	19.1	17.3		
KM Estimate: 1 Calendar Year	20.2	18.9		
KM Estimate: 18 Months	23.8	25.3		
KM Estimate: 24 Months	27.6	29.4		
KM Estimate: 2 Calendar Years	30.7	31		
KM Estimate: 30 Months	31.1	33.8		
KM Estimate: 36 Months	32.2	37.8		
KM Estimate: 3 Calendar Years	999	37.8		

Statistical analyses

Statistical analysis title	Difference in KM percentages
Comparison groups	Ranolazine v Placebo
Number of subjects included in analysis	2604
Analysis specification	Pre-specified
Analysis type	other ^[1]
P-value	= 0.48 ^[2]
Method	Cox Proportional Hazards Model
Parameter estimate	Hazard ratio (HR)
Point estimate	0.948
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.818
upper limit	1.099

Notes:

[1] - Comparative analysis

[2] - The p-value and hazard ratio are from Cox proportional hazards model stratifying by reason for qualifying percutaneous coronary intervention (PCI): acute coronary syndrome (ACS) versus non-ACS indication, and history of diabetes (yes versus no).

Secondary: Time From Randomization to Sudden Cardiac Death

End point title	Time From Randomization to Sudden Cardiac Death
End point description:	
Full Analysis Set. Time to event distributions were estimated by the Kaplan-Meier method. 1 month = 28 days; 1 calendar year = 365 days.	
End point type	Secondary
End point timeframe:	
Baseline through end of study (average 90 weeks)	

End point values	Ranolazine	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1317	1287		
Units: percentage of participants				
number (not applicable)				
KM Estimate: 1 Month	0.2	0.1		
KM Estimate: 6 Months	0.5	0.2		
KM Estimate: 12 Months	0.5	0.5		
KM Estimate: 1 Calendar Year	0.5	0.5		
KM Estimate: 18 Months	0.5	0.8		
KM Estimate: 24 Months	0.5	0.9		
KM Estimate: 2 Calendar Years	0.7	0.9		
KM Estimate: 30 Months	0.7	0.9		
KM Estimate: 36 Months	0.7	0.9		
KM Estimate: 3 Calendar Years	0.7	0.9		

Statistical analyses

Statistical analysis title	Difference in percentages
Comparison groups	Ranolazine v Placebo
Number of subjects included in analysis	2604
Analysis specification	Pre-specified
Analysis type	other ^[3]
P-value	= 0.4 ^[4]
Method	Cox Proportional Hazards Model
Parameter estimate	Hazard ratio (HR)
Point estimate	0.665
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.244
upper limit	1.691

Notes:

[3] - Comparative analysis

[4] - The p-value and hazard ratio are from Cox proportional hazards model stratifying by reason for qualifying PCI: ACS versus non-ACS indication, and history of diabetes (yes versus no).

Secondary: Time From Randomization to Cardiovascular Death

End point title	Time From Randomization to Cardiovascular Death
End point description:	
Full Analysis Set. Time to event distributions were estimated by the Kaplan-Meier method. 1 month = 28 days; 1 calendar year = 365 days.	
End point type	Secondary
End point timeframe:	
Baseline through end of study (average 90 weeks)	

End point values	Ranolazine	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1317	1287		
Units: percentage of participants				
number (not applicable)				
KM Estimate: 1 Month	0.2	0.1		
KM Estimate: 6 Months	0.6	0.4		
KM Estimate: 12 Months	1	0.9		
KM Estimate: 1 Calendar Year	1.1	1		
KM Estimate: 18 Months	1.5	1.4		
KM Estimate: 24 Months	1.7	1.7		
KM Estimate: 2 Calendar Years	1.9	1.7		
KM Estimate: 30 months	1.9	1.7		
KM Estimate: 36 months	1.9	1.7		
KM Estimate: 3 Calendar Years	1.9	1.7		

Statistical analyses

Statistical analysis title	Difference in KM percentages
Comparison groups	Ranolazine v Placebo
Number of subjects included in analysis	2604
Analysis specification	Pre-specified
Analysis type	other ^[5]
P-value	= 0.82 ^[6]
Method	Cox Proportional Hazards Model
Parameter estimate	Hazard ratio (HR)
Point estimate	1.073
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.579
upper limit	1.994

Notes:

[5] - Comparative analysis

[6] - The p-value and hazard ratio are from Cox proportional hazards model stratifying by reason for qualifying PCI: ACS versus non-ACS indication, and history of diabetes (yes versus no).

Secondary: Time From Randomization to Myocardial Infarction

End point title	Time From Randomization to Myocardial Infarction
End point description:	
Full Analysis Set. Time to event distributions were estimated by the Kaplan-Meier method. 1 month = 28 days; 1 calendar year = 365 days.	
End point type	Secondary
End point timeframe:	
Baseline through end of study (average 90 weeks)	

End point values	Ranolazine	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1317	1287		
Units: percentage of participants				
number (not applicable)				
KM Estimate: 1 Month	1.2	0.6		
KM Estimate: 6 Months	3.8	3.3		
KM Estimate: 12 Months	5.8	5.7		
KM Estimate: 1 Calendar Year	6.2	6.2		
KM Estimate: 18 Months	7.3	8.5		
KM Estimate: 24 Months	8.7	9.4		
KM Estimate: 2 Calendar Years	10	9.4		
KM Estimate: 30 months	10.9	10.1		
KM Estimate: 36 months	10.9	13.4		
KM Estimate: 3 Calendar Years	10.9	13.4		

Statistical analyses

Statistical analysis title	Difference in KM percentages
Comparison groups	Ranolazine v Placebo
Number of subjects included in analysis	2604
Analysis specification	Pre-specified
Analysis type	other ^[7]
P-value	= 0.81 ^[8]
Method	Cox Proportional Hazards Model
Parameter estimate	Hazard ratio (HR)
Point estimate	0.968
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.745
upper limit	1.256

Notes:

[7] - Comparative analysis

[8] - The p-value and hazard ratio are from Cox proportional hazards model stratifying by reason for qualifying PCI: ACS versus non-ACS indication, and history of diabetes (yes versus no).

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Baseline through end of study drug treatment (average exposure 72 weeks) plus 30 days

Adverse event reporting additional description:

Safety Analysis Set: participants who were randomized and received at least one dose of study drug

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	17.1
--------------------	------

Reporting groups

Reporting group title	Ranolazine
-----------------------	------------

Reporting group description:

Ranolazine 500 mg (1 x 500 mg tablet) for 7 days, followed by ranolazine 1000 mg (2 x 500 mg tablet) for the duration of the study (participants receiving a moderate CYP3A4 inhibitor continued to receive ranolazine 500 mg (1 x 500 mg tablet) for the duration of the study)

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Ranolazine placebo (1 tablet) for 7 days, followed by ranolazine placebo (2 tablets) for the duration of the study (participants receiving a moderate CYP3A4 inhibitor continued to receive ranolazine placebo (1 tablet) for the duration of the study)

Serious adverse events	Ranolazine	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	516 / 1322 (39.03%)	485 / 1297 (37.39%)	
number of deaths (all causes)	34	29	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Prostate cancer			
subjects affected / exposed	3 / 1322 (0.23%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder adenocarcinoma stage unspecified			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder neoplasm			

subjects affected / exposed	1 / 1322 (0.08%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder transitional cell carcinoma			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant melanoma			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of skin			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine cancer			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma of colon			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adrenal adenoma			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer stage 0, with cancer in situ			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchial carcinoma			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangiocarcinoma			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon neoplasm			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial cancer			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial cancer stage I			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibrous histiocytoma			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glioblastoma			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Leukaemia			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Lung adenocarcinoma			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung neoplasm			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Lung neoplasm malignant			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to peritoneum			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasm			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasm malignant			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal adenocarcinoma			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal carcinoma			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic carcinoma metastatic			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Plasma cell myeloma			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cell carcinoma			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salivary gland neoplasm			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small cell lung cancer			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Testis cancer			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroid neoplasm			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transitional cell carcinoma			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Peripheral ischaemia			
subjects affected / exposed	6 / 1322 (0.45%)	7 / 1297 (0.54%)	
occurrences causally related to treatment / all	0 / 8	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 2	
Hypertension			
subjects affected / exposed	9 / 1322 (0.68%)	3 / 1297 (0.23%)	
occurrences causally related to treatment / all	0 / 10	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral arterial occlusive disease			
subjects affected / exposed	4 / 1322 (0.30%)	7 / 1297 (0.54%)	
occurrences causally related to treatment / all	0 / 6	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral vascular disorder			
subjects affected / exposed	4 / 1322 (0.30%)	5 / 1297 (0.39%)	
occurrences causally related to treatment / all	0 / 5	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			
subjects affected / exposed	7 / 1322 (0.53%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	1 / 7	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic aneurysm			

subjects affected / exposed	5 / 1322 (0.38%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deep vein thrombosis			
subjects affected / exposed	4 / 1322 (0.30%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orthostatic hypotension			
subjects affected / exposed	4 / 1322 (0.30%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic stenosis			
subjects affected / exposed	3 / 1322 (0.23%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive crisis			
subjects affected / exposed	1 / 1322 (0.08%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intermittent claudication			
subjects affected / exposed	3 / 1322 (0.23%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery stenosis			
subjects affected / exposed	1 / 1322 (0.08%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombosis			
subjects affected / exposed	2 / 1322 (0.15%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive emergency			

subjects affected / exposed	2 / 1322 (0.15%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant hypertension			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial stenosis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriosclerosis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extremity necrosis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femoral artery occlusion			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypovolaemic shock			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Ischaemia			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphorrhoea			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery thrombosis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renovascular hypertension			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subclavian vein thrombosis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varicose vein			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	37 / 1322 (2.80%)	24 / 1297 (1.85%)	
occurrences causally related to treatment / all	0 / 39	0 / 27	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-cardiac chest pain			
subjects affected / exposed	19 / 1322 (1.44%)	19 / 1297 (1.46%)	
occurrences causally related to treatment / all	0 / 20	0 / 21	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest discomfort			
subjects affected / exposed	2 / 1322 (0.15%)	3 / 1297 (0.23%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			

subjects affected / exposed	2 / 1322 (0.15%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthenia			
subjects affected / exposed	3 / 1322 (0.23%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery restenosis			
subjects affected / exposed	1 / 1322 (0.08%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multi-organ failure			
subjects affected / exposed	0 / 1322 (0.00%)	3 / 1297 (0.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 2	
Sudden cardiac death			
subjects affected / exposed	2 / 1322 (0.15%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 2	0 / 1	
Arterial restenosis			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Death			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Fatigue			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery restenosis			

subjects affected / exposed	1 / 1322 (0.08%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery restenosis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device extrusion			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device malfunction			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Face oedema			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impaired healing			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multi-organ disorder			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Oedema peripheral			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombosis in device			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ulcer haemorrhage			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Drug hypersensitivity			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Benign prostatic hyperplasia			
subjects affected / exposed	0 / 1322 (0.00%)	4 / 1297 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatitis			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epididymal cyst			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	13 / 1322 (0.98%)	13 / 1297 (1.00%)	
occurrences causally related to treatment / all	0 / 15	0 / 18	
deaths causally related to treatment / all	0 / 0	0 / 1	
Chronic obstructive pulmonary disease			

subjects affected / exposed	5 / 1322 (0.38%)	7 / 1297 (0.54%)	
occurrences causally related to treatment / all	0 / 6	0 / 8	
deaths causally related to treatment / all	0 / 1	0 / 0	
Dyspnoea exertional			
subjects affected / exposed	2 / 1322 (0.15%)	4 / 1297 (0.31%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary oedema			
subjects affected / exposed	2 / 1322 (0.15%)	4 / 1297 (0.31%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Epistaxis			
subjects affected / exposed	1 / 1322 (0.08%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	1 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			
subjects affected / exposed	1 / 1322 (0.08%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax			
subjects affected / exposed	1 / 1322 (0.08%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	1 / 1322 (0.08%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			
subjects affected / exposed	2 / 1322 (0.15%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute respiratory failure			

subjects affected / exposed	1 / 1322 (0.08%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthma			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis chronic			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoptysis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoxia			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngeal stenosis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung consolidation			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngeal haemorrhage			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia aspiration			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax spontaneous			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary congestion			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary fibrosis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary hypertension			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Respiratory disorder			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory distress			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Tonsillar hypertrophy			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheal stenosis			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Mental status changes			
subjects affected / exposed	2 / 1322 (0.15%)	4 / 1297 (0.31%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression			
subjects affected / exposed	3 / 1322 (0.23%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Delusional disorder, unspecified type			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Major depression			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicidal ideation			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Cardiac stress test abnormal			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ejection fraction decreased			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrocardiogram ST segment			

depression			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic enzyme increased			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Head injury			
subjects affected / exposed	3 / 1322 (0.23%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Laceration			
subjects affected / exposed	1 / 1322 (0.08%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip fracture			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Overdose			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rib fracture			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Road traffic accident			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Anaemia postoperative			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest injury			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Concussion			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Craniocerebral injury			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial bones fracture			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fall			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femur fracture			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot fracture			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Graft thrombosis			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Humerus fracture			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb injury			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower limb fracture			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar vertebral fracture			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle rupture			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic fracture			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Periorbital haematoma			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral arterial reocclusion			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural complication			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural fistula			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haematoma			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haemorrhage			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative hernia			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative wound complication			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postpericardiotomy syndrome			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural pain			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pubis fracture			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subcutaneous haematoma			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haematoma			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haemorrhage			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper limb fracture			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular graft complication			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular pseudoaneurysm			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital, familial and genetic disorders			
Atrial septal defect			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	125 / 1322 (9.46%)	114 / 1297 (8.79%)	
occurrences causally related to treatment / all	0 / 146	0 / 135	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina unstable			
subjects affected / exposed	58 / 1322 (4.39%)	71 / 1297 (5.47%)	
occurrences causally related to treatment / all	0 / 66	0 / 79	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute myocardial infarction			
subjects affected / exposed	28 / 1322 (2.12%)	29 / 1297 (2.24%)	
occurrences causally related to treatment / all	0 / 31	0 / 31	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial infarction			
subjects affected / exposed	18 / 1322 (1.36%)	18 / 1297 (1.39%)	
occurrences causally related to treatment / all	0 / 19	0 / 19	
deaths causally related to treatment / all	0 / 5	0 / 2	
Atrial fibrillation			
subjects affected / exposed	12 / 1322 (0.91%)	14 / 1297 (1.08%)	
occurrences causally related to treatment / all	0 / 14	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure congestive			
subjects affected / exposed	20 / 1322 (1.51%)	6 / 1297 (0.46%)	
occurrences causally related to treatment / all	0 / 28	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 1	
Coronary artery disease			
subjects affected / exposed	14 / 1322 (1.06%)	11 / 1297 (0.85%)	
occurrences causally related to treatment / all	0 / 15	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cardiac failure			

subjects affected / exposed	11 / 1322 (0.83%)	12 / 1297 (0.93%)	
occurrences causally related to treatment / all	0 / 14	0 / 19	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial ischaemia			
subjects affected / exposed	8 / 1322 (0.61%)	12 / 1297 (0.93%)	
occurrences causally related to treatment / all	0 / 8	0 / 16	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute coronary syndrome			
subjects affected / exposed	2 / 1322 (0.15%)	9 / 1297 (0.69%)	
occurrences causally related to treatment / all	0 / 2	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular tachycardia			
subjects affected / exposed	5 / 1322 (0.38%)	4 / 1297 (0.31%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Bradycardia			
subjects affected / exposed	5 / 1322 (0.38%)	3 / 1297 (0.23%)	
occurrences causally related to treatment / all	0 / 5	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac arrest			
subjects affected / exposed	5 / 1322 (0.38%)	3 / 1297 (0.23%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 4	0 / 3	
Ischaemic cardiomyopathy			
subjects affected / exposed	2 / 1322 (0.15%)	4 / 1297 (0.31%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Atrial flutter			
subjects affected / exposed	5 / 1322 (0.38%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 5	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure acute			

subjects affected / exposed	2 / 1322 (0.15%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery stenosis			
subjects affected / exposed	2 / 1322 (0.15%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mitral valve incompetence			
subjects affected / exposed	3 / 1322 (0.23%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachycardia			
subjects affected / exposed	2 / 1322 (0.15%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular fibrillation			
subjects affected / exposed	1 / 1322 (0.08%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Arrhythmia supraventricular			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriosclerosis coronary artery			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Atrioventricular block			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block second degree			

subjects affected / exposed	0 / 1322 (0.00%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure chronic			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardio-respiratory arrest			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Cardiogenic shock			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Coronary artery occlusion			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Left ventricular dysfunction			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postinfarction angina			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Supraventricular tachycardia			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular arrhythmia			

subjects affected / exposed	0 / 1322 (0.00%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arrhythmia			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block complete			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block first degree			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac tamponade			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiopulmonary failure			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cardiorenal syndrome			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Conduction disorder			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cor pulmonale			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Coronary artery insufficiency			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Myocardial rupture			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Palpitations			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Right ventricular dysfunction			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus arrest			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus arrhythmia			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus bradycardia			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus tachycardia			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular dysfunction			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular tachyarrhythmia			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wolff-Parkinson-White syndrome			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericarditis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Syncope			
subjects affected / exposed	25 / 1322 (1.89%)	13 / 1297 (1.00%)	
occurrences causally related to treatment / all	3 / 30	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular accident			
subjects affected / exposed	12 / 1322 (0.91%)	9 / 1297 (0.69%)	
occurrences causally related to treatment / all	0 / 12	0 / 9	
deaths causally related to treatment / all	0 / 3	0 / 0	
Transient ischaemic attack			
subjects affected / exposed	12 / 1322 (0.91%)	3 / 1297 (0.23%)	
occurrences causally related to treatment / all	0 / 14	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Presyncope			

subjects affected / exposed	9 / 1322 (0.68%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	1 / 10	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery stenosis			
subjects affected / exposed	8 / 1322 (0.61%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 9	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness			
subjects affected / exposed	5 / 1322 (0.38%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	1 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic stroke			
subjects affected / exposed	5 / 1322 (0.38%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Headache			
subjects affected / exposed	2 / 1322 (0.15%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	1 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral infarction			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Lacunar infarction			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Loss of consciousness			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myelopathy			

subjects affected / exposed	1 / 1322 (0.08%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Balance disorder			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain oedema			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Carotid artery aneurysm			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery dissection			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery occlusion			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebellar infarction			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral haematoma			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral haemorrhage			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysarthria			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Generalised tonic-clonic seizure			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Guillain-Barre syndrome			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic transformation stroke			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intracranial pressure increased			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Lateral medullary syndrome			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar radiculopathy			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mononeuropathy			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle contractions involuntary			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myasthenia gravis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paraesthesia			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radicular pain			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sciatica			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subarachnoid haemorrhage			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxic encephalopathy			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tremor			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebral artery stenosis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	10 / 1322 (0.76%)	3 / 1297 (0.23%)	
occurrences causally related to treatment / all	0 / 10	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iron deficiency anaemia			
subjects affected / exposed	2 / 1322 (0.15%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukocytosis			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenopathy			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Normochromic normocytic anaemia			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Platelet dysfunction			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			

Vertigo			
subjects affected / exposed	1 / 1322 (0.08%)	3 / 1297 (0.23%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vestibular disorder			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Cataract			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyphaema			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal detachment			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Gastrointestinal haemorrhage			
subjects affected / exposed	8 / 1322 (0.61%)	13 / 1297 (1.00%)	
occurrences causally related to treatment / all	0 / 9	0 / 15	
deaths causally related to treatment / all	0 / 1	0 / 0	
Vomiting			
subjects affected / exposed	4 / 1322 (0.30%)	3 / 1297 (0.23%)	
occurrences causally related to treatment / all	1 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal haemorrhage			
subjects affected / exposed	6 / 1322 (0.45%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 6	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Abdominal pain			
subjects affected / exposed	3 / 1322 (0.23%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	4 / 1322 (0.30%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	1 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia			
subjects affected / exposed	2 / 1322 (0.15%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis ischaemic			
subjects affected / exposed	3 / 1322 (0.23%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	3 / 1322 (0.23%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer			
subjects affected / exposed	1 / 1322 (0.08%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus			
subjects affected / exposed	2 / 1322 (0.15%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain upper			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis			

subjects affected / exposed	2 / 1322 (0.15%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenitis			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal perforation			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Lower gastrointestinal haemorrhage			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retroperitoneal haematoma			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal discomfort			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal hernia			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain lower			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal fissure			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ascites			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic gastrointestinal bleeding			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Crohn's disease			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticular perforation			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum intestinal			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysphagia			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis erosive			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal perforation			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal polyp haemorrhage			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematemesis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematochezia			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoids			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus paralytic			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal angina			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal haemorrhage			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal mass			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal obstruction			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intra-abdominal haemorrhage			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Large intestine polyp			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lip disorder			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mesenteric artery thrombosis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophagitis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis acute			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis chronic			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Proctitis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radicular cyst			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal ulcer haemorrhage			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholecystitis acute			
subjects affected / exposed	2 / 1322 (0.15%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholelithiasis			
subjects affected / exposed	1 / 1322 (0.08%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary colic			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic cirrhosis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			

Angioedema			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic foot			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dry gangrene			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperhidrosis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psoriasis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash generalised			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin lesion			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin ulcer			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Renal failure acute			
subjects affected / exposed	5 / 1322 (0.38%)	6 / 1297 (0.46%)	
occurrences causally related to treatment / all	0 / 6	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematuria			
subjects affected / exposed	1 / 1322 (0.08%)	4 / 1297 (0.31%)	
occurrences causally related to treatment / all	0 / 1	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			
subjects affected / exposed	4 / 1322 (0.30%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	1 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary retention			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder outlet obstruction			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic nephropathy			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephropathy			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrotic syndrome			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal artery stenosis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal colic			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure chronic			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Renal infarct			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary incontinence			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Hyperthyroidism			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adrenal insufficiency			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			

Osteoarthritis			
subjects affected / exposed	5 / 1322 (0.38%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back pain			
subjects affected / exposed	2 / 1322 (0.15%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal chest pain			
subjects affected / exposed	2 / 1322 (0.15%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhabdomyolysis			
subjects affected / exposed	2 / 1322 (0.15%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	2 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rotator cuff syndrome			
subjects affected / exposed	2 / 1322 (0.15%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal column stenosis			
subjects affected / exposed	0 / 1322 (0.00%)	3 / 1297 (0.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthralgia			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar spinal stenosis			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal pain			

subjects affected / exposed	2 / 1322 (0.15%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neck pain			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal osteoarthritis			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical spinal stenosis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc protrusion			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myalgia			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neck mass			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteochondrosis			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polyarthritis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psoriatic arthropathy			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal disorder			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Pneumonia			
subjects affected / exposed	14 / 1322 (1.06%)	12 / 1297 (0.93%)	
occurrences causally related to treatment / all	0 / 14	0 / 12	
deaths causally related to treatment / all	0 / 1	0 / 0	
Urinary tract infection			
subjects affected / exposed	2 / 1322 (0.15%)	6 / 1297 (0.46%)	
occurrences causally related to treatment / all	0 / 2	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	5 / 1322 (0.38%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 7	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	6 / 1322 (0.45%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 6	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis			

subjects affected / exposed	3 / 1322 (0.23%)	3 / 1297 (0.23%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			
subjects affected / exposed	1 / 1322 (0.08%)	4 / 1297 (0.31%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			
subjects affected / exposed	4 / 1322 (0.30%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	3 / 1322 (0.23%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis acute			
subjects affected / exposed	1 / 1322 (0.08%)	3 / 1297 (0.23%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic shock			
subjects affected / exposed	3 / 1322 (0.23%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Abscess limb			
subjects affected / exposed	2 / 1322 (0.15%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis			
subjects affected / exposed	2 / 1322 (0.15%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urosepsis			

subjects affected / exposed	2 / 1322 (0.15%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Wound infection			
subjects affected / exposed	1 / 1322 (0.08%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchopneumonia			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bursitis infective			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related infection			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erysipelas			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis viral			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal wall abscess			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess neck			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis perforated			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis bacterial			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis infective			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile colitis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile infection			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Creutzfeldt-Jakob disease			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cystitis			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea infectious			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocarditis bacterial			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolitis bacterial			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gingival abscess			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Groin abscess			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster oticus			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infection			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Localised infection			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orchitis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis acute			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis externa			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative abscess			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative wound infection			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary tuberculosis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection viral			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis syndrome			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin infection			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subcutaneous abscess			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tuberculosis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection bacterial			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral upper respiratory tract infection			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Hypoglycaemia			
subjects affected / exposed	4 / 1322 (0.30%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	4 / 6	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	4 / 1322 (0.30%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkalaemia			

subjects affected / exposed	4 / 1322 (0.30%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration			
subjects affected / exposed	2 / 1322 (0.15%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			
subjects affected / exposed	2 / 1322 (0.15%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokalaemia			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1297 (0.15%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypovolaemia			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus inadequate control			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic ketoacidosis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrolyte imbalance			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fluid overload			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gout			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypomagnesaemia			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1297 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Ranolazine	Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	655 / 1322 (49.55%)	531 / 1297 (40.94%)	
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	161 / 1322 (12.18%)	156 / 1297 (12.03%)	
occurrences (all)	211	199	
Nervous system disorders			
Dizziness			
subjects affected / exposed	240 / 1322 (18.15%)	119 / 1297 (9.18%)	
occurrences (all)	275	135	
Headache			
subjects affected / exposed	98 / 1322 (7.41%)	89 / 1297 (6.86%)	
occurrences (all)	113	101	
General disorders and administration site conditions			

Chest pain			
subjects affected / exposed	97 / 1322 (7.34%)	92 / 1297 (7.09%)	
occurrences (all)	115	105	
Fatigue			
subjects affected / exposed	99 / 1322 (7.49%)	74 / 1297 (5.71%)	
occurrences (all)	104	77	
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	167 / 1322 (12.63%)	71 / 1297 (5.47%)	
occurrences (all)	184	73	
Nausea			
subjects affected / exposed	123 / 1322 (9.30%)	63 / 1297 (4.86%)	
occurrences (all)	137	69	
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	89 / 1322 (6.73%)	89 / 1297 (6.86%)	
occurrences (all)	104	98	
Cough			
subjects affected / exposed	69 / 1322 (5.22%)	51 / 1297 (3.93%)	
occurrences (all)	72	56	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
29 September 2011	Clarified that the primary and secondary endpoint events were adjudicated; included a more conservative statistical approach to multiple testing of the secondary endpoints.
29 November 2011	Included a recommendation for investigators to closely monitor subjects concomitantly taking drugs that were known to affect the QTc intervals; included a recommendations for investigators to exercise caution when administering ranolazine in subjects with a history of congenital or a family history of a long QT syndrome as well as in subjects with known acquired QT interval prolongation.
15 February 2012	Revised and clarified the primary and secondary endpoint events adjudication; added heart failure hospitalizations as a safety endpoint; added new inclusion criterion to clarify that subjects must have been randomized within 14 days of the index PCI; added new exclusion criterion to prohibit concomitant use of metformin at total daily doses > 1000 mg; clarified the requirements for creatinine kinase-MB (CK-MB) and troponin I/T testing; clarified the study drug dosing restrictions in subjects who received any moderate cytochrome P450 enzyme (CYP) 3A4 inhibitor, not just verapamil or diltiazem; added the submission to the core laboratory of written results for stress tests performed within 3 months prior to the index PCI.
25 October 2012	Broadened the qualifying time frame for establishing a history of chronic angina; allowed incomplete revascularization in a single coronary territory to qualify in the absence of additional enriching criteria for subjects undergoing index percutaneous coronary intervention for non-acute coronary syndrome

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

There were no limitations affecting the analysis or results.

Notes:

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/24268208>

<http://www.ncbi.nlm.nih.gov/pubmed/26474810>

<http://www.ncbi.nlm.nih.gov/pubmed/26555329>